The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

European Journal of Clinical Pharmacology

Volumn 54, Issue 1, 1998, Pages 53-58

  Backman, J T ^a   Kivisto K T ^a   Olkkola, K T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Itraconazole; Midazolam; Rifampicin

Indexed keywords

ANTIFUNGAL AGENT; BENZODIAZEPINE; ITRACONAZOLE; MIDAZOLAM; MIDAZOLAM MALEATE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031959294     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050420     Document Type: Article

References (25)

1. Fabre G, Rahmani R, Placidi M, Combalbert J, Covo J, Cano JP. Coulange C. Ducros M. Rampal M (1988) Characterizalion of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 37: 4389-4397
2. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643 1653
3. 14C-midazolam in humans following oral dosing. Arzneimittelforchung 31: 2220 2223
4. Kronbach T, Mathys D, Umeno M, Gonzales FJ. Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89 96
5. Wandel C, Böcker R, Böhrer H, Browne A. Rüghcimer H. Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73: 658 661
6. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use of midazolam as a human cytochrome P450 3A probe. I. In vitro in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271: 549 556
7. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use ol midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271: 557 566
8. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171 184
9. Paine MF, Shen DD, Kunze KL. Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60: 14-24
10. Thummel KE, O'Shea D, Paine ME, Shen DD, Kunze KL, Perkins JD, Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491 502
11. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should he avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55: 481-485
12. Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59: 7 13
13. Ha HR. Rentsch KM, Kneer J, Vonderschmitt DJ (1993) Determination of midazolam and its α-hydroxymetabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 15: 338 343
14. Allenmark S, Edebo A, Lindgren K (1990) Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 532: 203 206
15. Remmel RP, Dombrowskis D, Canafax DM (1988) Assay of itraconazole in leucemic patient plasma by reverse-phase small-bore liquid chromatography. J Chromatogr 432: 388 394
16. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker. New York
17. Heizmann P, Eckert M. Ziegler WH ( 1983) Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16: 43S 49S
18. IS. Allonen H, Ziegler G, Klotz U (1981) Midazolam kinetics. Clin Pharmacol Ther 30: 653 661
19. Back DJ. Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole. itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32: 624-626
20. Hargreaves JA. Jezequel S, Houston JB (1994) Effects of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38: 175P
21. Kolars JC, Schmiedlin-Ren P. Schuetz JD. Fang C. Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871 1878
22. Pichard L, Fabre I, Fabre G. Domergue J, Saint Aubert B, Mourad G. Maurel P (1990) Cyclosporin A drug interactions: screening for indueers and inhibitors of cytochrome P-450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18: 595 606
23. Mandema JW, Tuk B. van Stevenick AL, Breimer DD, Cohen AF, Danhof M (1992) Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51: 715 728
24. Grant SM, Clissold SP (1989) Itraconazole: a review of its pharmacokinetic and pharmacodynamic properties and therapeutic use in superficial and systemic mycoses. Drugs 37: 310 344
25. Fromm MF, Busse D, Kroemer HK, Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796 801